FORT WORTH, Texas, July 21, 2021 / PRNewswire / – FDS Amplicare, a leading provider of pharmaceutical technology, and its training partners, Don and Mike Klepser, both professors of pharmacy and leading experts in the field of point-of-care testing (POCT), strongly support the continued expansion of community pharmacies as CLIA-exempt establishments. Pharmacies have increasingly become a key source for consumer access to point-of-care diagnostic tests provided by CLIA.
Researchers Don klepser, PhD, MBA and Mike Klepser, PharmD, FCCP, recently published in Research in Social and Administrative Pharmacy, are available for media interviews to discuss their research which shows pharmacies are now the second largest provider of CLIA-exempt tests by total number of locations, behind the only doctor in the offices. They found that the number of pharmacies with CLIA exemption certificates jumped 45% to 15,671 from 2015 to 2020. Most of the growth occurred between 2019 and 2020, suggesting that growing consumer demand for COVID-19 diagnostic testing was behind the increase in CLIA certificates. waiver.
Jason ausili, Chief Clinical Director of FDS Amplicare, is available for media interviews on how community pharmacies can implement a practice of point-of-care testing during this unprecedented time. Administrative barriers have been relaxed and the CLIA waiver request and Supplier Transaction Access Number (PTAN) processes have been speeded up to help clear the way for those interested.
Context of CLIA waivers:
The US Clinical Laboratory Improvement Amendments of 1988 (CLIA) provided better access to simple, low-risk (CLIA-waived) tests by allowing their use in facilities such as pharmacies, long-term care facilities, and nursing homes. doctors’ offices. To administer the exempted CLIA tests, these facilities must obtain a CLIA exemption certificate from the United States Centers for Medicare and Medicaid Services.
The COVID-19 pandemic recently placed emphasis on diagnostic tests exempt from CLIA, as the lack of a vaccine or effective treatment in the early days of the pandemic made diagnostic tests one of the few tools to control the spread of the virus. To meet this increased patient demand for diagnostic testing, the federal government has allowed licensed pharmacists to order and administer licensed COVID-19 tests, attributing the decision to the close relationships pharmacists have with patients and providers. health care as well as the convenient proximity of pharmacies to most Americans.
The recent increase in CLIA exemption certificates illustrates that pharmacies have seized the opportunity to further assert themselves as health care centers in their communities. However, to reap the full benefits, pharmacies must adopt the operational tools, training, and software solutions necessary to transparently bill payers for CLIA-exempt tests, in addition to patient communication platforms to support the commitment.
To arrange an interview, please contact [email protected]
About FDS Amplicare
FDS Amplicare strengthens the health of pharmacies and their patients. We empower community pharmacies to create the clinic-focused New Era Pharmacy, enabling their business to thrive now and successfully transition to a community and population health provider through data insights, solutions specially designed technologies and activation of clinical services. Learn more about FDS Amplicare at www.fdsrx.com and www.amplicare.com.
SOURCE SDS Amplicare